Home > Insider Trading > Filing (0001209191-20-060791)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1714899	Denali Therapeutics Inc.	DNLI	Biological Products, (No Disgnostic Substances) (2836)	463872213

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1724605	Carole Ho	C/O Denali Therapeutics Inc. 161 Oyster Point Blvd. South San Francisco CA 94080	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-12-03	17,500	$5.28	195,625	No	4	M	Indirect	See footnote
Common Stock	Disposition	2018-12-03	17,100	$18.43	178,525	No	4	S	Indirect	See footnote
Common Stock	Disposition	2018-12-03	400	$19.16	178,125	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Acquisiton	2018-12-03	17,500	$0.00	17,500	$5.28

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
84,375		2026-07-01	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	46,875	Direct
Common Stock	25,000	Indirect	See footnote

Footnotes

The shares are held of record by Carole Ho and Rajat Rohatgi.
Shares held of record by The Rohatgi-Ho Irrevocable GST Trust.
The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.07 to $18.87 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.15 to $19.17 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Of the total 125,000 shares granted, 25% of the shares subject to the option vested on July 2, 2017 and an additional 1/48 of the shares vest monthly thereafter.